
|Videos|October 25, 2013
Ovarian Cancer Maintenance Therapy With Bevacizumab
Author(s)Robert A. Burger, MD
Robert A. Burger, MD, Professor, Department of Surgical Oncology, Director, Women’s Cancer Center, Fox Chase Cancer Center, discusses ovarian cancer maintenance with bevacizumab.
Advertisement
Clinical Pearls
Robert A. Burger, MD, Professor, Department of Surgical Oncology, Director, Women’s Cancer Center, Fox Chase Cancer Center, discusses ovarian cancer maintenance with bevacizumab.
- In frontline trials, bevacizumab was administered with a maximum number of treatment cycles beyond chemotherapy
- In second-line trials, maintenance therapy was continued until disease progression
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
4
Early Relapse Guides Use of CAR T vs Other Options in LBCL
5








































